Constellation Brands Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Constellation Brands Inc. Common Stock trades at $129.15 (market cap $21.56B), while Twist Bioscience Corp trades at $141.01 (market cap $9.82B). The key difference: Constellation Brands Inc. Common Stock is far larger — about 2.2× Twist Bioscience Corp's market cap, and Constellation Brands Inc. Common Stock pays a 3.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| STZ | TWST | |
|---|---|---|
Market Cap | $21.56B | $9.82B |
Volume | 1,626,934 | 2,115,226 |
Sector | Consumer Staples | Health |
52-Week High | $166.68 | $205.00 |
52-Week Low | $112.77 | $25.45 |
Enterprise Value | $31.78B | $9.75B |
Dividend Yield | 3.23% | — |
Typical Hold Time | — | 27 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Constellation Brands, Inc. is a US producer and marketer of beer, wine, and spirits, known for importing Mexican beer brands Corona and Modelo alongside a portfolio of wine and craft spirits labels.
Read more on STZ →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →